Firm News

Home 9 News Item 9 Wiggin and Dana Advises Aptar Pharma in Acquisition of Mod 3 Pharma

Wiggin and Dana Advises Aptar Pharma in Acquisition of Mod 3 Pharma

July 15, 2025

Wiggin and Dana recently represented Aptar Pharma, a leader in drug delivery and active material science solutions and services, in its acquisition of the clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. This move strengthens Aptar’s support for early-stage drug development by offering formulation, fill and finish services for Phase 1 and 2 clinical trials and enhances adoption of its proprietary devices in early-stage clinical programs.

The Wiggin deal team consisted of Patti Melick, Heather Rahilly, Brittany Lyon, and Selma Tabakovic.

To learn more, click here.

Resources

Firm Highlights